share_log

Connect Biopharma | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-RA Capital Management, L.P.(0%),Peter Kolchinsky(0%), etc.

SEC announcement ·  Feb 27 16:28
Summary by Moomoo AI
On February 23, 2024, RA Capital Management, L.P., along with individuals Peter Kolchinsky and Rajeev Shah, and RA Capital Healthcare Fund, L.P., collectively known as the Reporting Persons, filed an amendment to their Schedule 13D with the SEC, indicating a change in their holdings of Connect Biopharma Holdings Limited. The filing, identified as Amendment No. 5, reported that the Reporting Persons sold a significant number of American Depositary Shares (ADSs) of Connect Biopharma. Specifically, the Fund sold 2,623,596 ADSs and The Nexus Fund sold 439,275 ADSs, both at a price of $0.9802 per ADS on February 23, 2024. As a result of these transactions, the Reporting Persons' beneficial ownership in Connect Biopharma dropped below five percent, leading to this filing being their exit filing from the company's securities. The Reporting Persons have thus ceased to be the beneficial owners of more than five percent of the Ordinary Shares of Connect Biopharma, and this amendment serves as their final amendment to the Schedule 13D, effectively concluding their filing obligations for this stake.
On February 23, 2024, RA Capital Management, L.P., along with individuals Peter Kolchinsky and Rajeev Shah, and RA Capital Healthcare Fund, L.P., collectively known as the Reporting Persons, filed an amendment to their Schedule 13D with the SEC, indicating a change in their holdings of Connect Biopharma Holdings Limited. The filing, identified as Amendment No. 5, reported that the Reporting Persons sold a significant number of American Depositary Shares (ADSs) of Connect Biopharma. Specifically, the Fund sold 2,623,596 ADSs and The Nexus Fund sold 439,275 ADSs, both at a price of $0.9802 per ADS on February 23, 2024. As a result of these transactions, the Reporting Persons' beneficial ownership in Connect Biopharma dropped below five percent, leading to this filing being their exit filing from the company's securities. The Reporting Persons have thus ceased to be the beneficial owners of more than five percent of the Ordinary Shares of Connect Biopharma, and this amendment serves as their final amendment to the Schedule 13D, effectively concluding their filing obligations for this stake.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more